High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patientsHigh incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients, Published online: 19 March 2019; doi:10.1038/s41409-019-0508-2High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

Source: Bone Marrow Transplantation - March 18, 2019 Category: Hematology Authors: Irene Prediletto Sarah A. Farag Ulrike Bacher Barbara Jeker Behrouz Mansouri Taleghani Rachel Br égy Thilo Zander Daniel Betticher Thomas Egger Urban Novak Thomas Pabst Source Type: research